双重序贯除颤治疗院外难治性心室颤动:范围综述
本范围综述检索了MEDLINE、Embase和Scopus(2019年8月19日),纳入成人(≥18岁)院外难治性室颤/无脉性室速心脏骤停接受双重序贯除颤的研究,共纳入4篇同行评议文章、1061例患者,其中20.5%(n=217)接受了双重序贯除颤;未发现随机对照试验。多数研究评估院前双重序贯除颤是否与改善出院生存相关。作者结论认为,基于现有证据难以判断双重序贯除颤的真实获益,支持大规模使用的证据有限,需进一步研究。
要点
- 范围综述纳入4篇同行评议文章、共1061例成人院外难治性室颤/无脉性室速心脏骤停患者,其中20.5%(n=217)接受了双重序贯除颤。
- 未发现随机对照试验,多数研究评估院前双重序贯除颤是否与改善出院生存相关。
- 作者结论认为,基于现有证据难以判断双重序贯除颤的真实获益,支持大规模使用的证据有限。
- 作者指出需进一步研究以更好刻画和理解双重序贯除颤的使用,从而实施最佳实践。
适用人群与场景
- 成人(≥18岁)院外难治性室颤/无脉性室速心脏骤停患者。
研究设计与关键结果
- 研究类型为范围综述,检索MEDLINE via PubMed、Embase via Ovid和Scopus(2019年8月19日),并核查相关论文参考文献。
- 检索获得1612条唯一记录,最终纳入4篇同行评议文章,共1061例患者,其中20.5%(n=217)接受了双重序贯除颤。
- 纳入研究设计包括随机对照试验、非随机对照试验、队列研究和病例对照研究;未发现随机对照试验。
- 多数研究评估院前双重序贯除颤是否与难治性室颤/无脉性室速心脏骤停后出院生存改善相关。
证据类型、等级与局限
- 证据类型:范围综述,纳入4篇同行评议文章(观察性研究为主),未发现随机对照试验。
- 作者结论:基于现有证据难以判断双重序贯除颤的真实获益,支持大规模使用的证据有限。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,目前支持在大规模范围内对院外难治性室颤/无脉性室速心脏骤停使用双重序贯除颤的证据有限。
- 作者指出需进一步研究以更好刻画和理解双重序贯除颤的使用,从而实施最佳实践以最大化救治的有效性和效率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Double sequential defibrillation (DSD) has been proposed as a viable treatment option for patients in refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT) out-of-hospital cardiac arrests (OHCA). However, currently there is insufficient evidence to support a widespread implementation of this therapy.
STUDY OBJECTIVES: The aim of this scoping review was to summarize the current available evidence of DSD for patients with refractory VF/pVT OHCA as well as to identify gaps in the literature that may require further research.
METHODS: We conducted a comprehensive literature search of MEDLINE via PubMed, Embase via Ovid, and Scopus on August 19, 2019. We also checked reference lists of relevant papers to identify additional studies. Any controlled clinical study design (randomized controlled trials and non-randomized controlled trials), and observational studies (cohort studies and case-control studies) providing information on resuscitative parameters, survival rates and neurological outcomes in adults (≥ 18 years old) treated with DSD for refractory VF/pVT OHCA were included. Two investigators independently conducted the literature search, study selection, and data extraction.
RESULTS: The search yielded 1612 unique records, of which 4 peer-reviewed articles were found relating to the research purpose, totaling 1061 patients of who 20.5% (n = 217) received DSD. Most studies evaluated if pre-hospital DSD was associated with improved survival to discharge after refractory VF/pVT. No randomized controlled trials were identified.
CONCLUSION: To date, it is difficult to conclude the real benefit of DSD for patients in refractory VF based on the available evidence. The findings of this scoping review suggest there is limited evidence to support at large-scale the use of DSD for refractory VF/pVT OHCA. Further research is needed to better characterize and understand the use of DSD for refractory VF/pVT, in order to implement best practices to maximize the effectiveness and efficiency of care.
参考来源
- Miraglia D, Miguel LA, Alonso W, et al. Double sequential defibrillation for out-of-hospital refractory ventricular fibrillation: A scoping review. Am J Emerg Med. 2019. PMID: 31937443. doi:10.1016/j.ajem.2019.12.047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。